Arnold Reynaldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arnold Reynaldi has a total of 395 co-authors. Here are the top co-authors by number of shared publications:
- Miles Philip Davenport
Kirby Institute University of New South Wales Kensington NSW Australia
38 shared publications - Stephen John Kent
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
23 shared publications - Adam Kenneth Wheatley
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
18 shared publications - Deborah Cromer
Kirby Institute, University of New South Wales, Sydney, NSW, Australia
14 shared publications - Jennifer A. Juno
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
14 shared publications - David S. Khoury
Kirby Institute, University of New South Wales, Sydney, NSW, Australia
13 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (11) , e70126
Randomised controlled phase I trial of a SARS ‐ CoV ‐2 monoclonal antibody
Objectives: SARS‐CoV‐2 infection remains a threat to vulnerable groups. Neutralising monoclonal antibodies (mAbs) have shown efficacy in the treatment and prevention of COVID‐19, but most mAbs have lost activity against recent Omicron strains. Methods: We previously isolated a receptor binding domain‐specific mAb from a COVID‐19 convalescent donor, PDI204, which retained activity against several early Omicron strains. This randomised, double‐blind, placebo‐controlled phase I clinical trial enrolled healthy adults ( n = 32) to receive PDI204 intravenously (IV) at three different doses (200, 600, 1200 mg) or intramuscularly (IM) at 300 mg. Results: PDI204 was safe and tolerable with only Grade 1 and 2 adverse events. High serum levels of PDI204 were detected in PDI204‐dosed participants with a median elimination half‐life of 17.7 days (IQR 16.3–22.1). Boosted neutralising activity and Fc receptor binding were observed in serum against ancestral and Omicron BA.5 SARS‐CoV‐2 strains, but not against the later Omicron strain XBB.1.5. IM‐dosed subjects had peak PDI204 levels in serum 2–6 days later than IV‐dosed subjects. Entry of PDI204 into saliva from blood was low and variable, and primarily detected in participants receiving 600 mg or 1200 mg doses. Three of 32 people acquired COVID‐19 within 90 days of dosing, two receiving PDI204 and one in a placebo recipient. Conclusion: Overall, the mAb PDI204 was safe but lost activity against later Omicron strains and did not prevent COVID‐19 during this trial.
- 4 November 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (11) , e70126
Open AccessRandomised controlled phase I trial of a SARS ‐ CoV ‐2 monoclonal antibody
Objectives: SARS‐CoV‐2 infection remains a threat to vulnerable groups. Neutralising monoclonal antibodies (mAbs) have shown efficacy in the treatment and prevention of COVID‐19, but most mAbs have lost activity against recent Omicron strains. Methods: We previously isolated a receptor binding domain‐specific mAb from a COVID‐19 convalescent donor, PDI204, which retained activity against several early Omicron strains. This randomised, double‐blind, placebo‐controlled phase I clinical trial enrolled healthy adults ( n = 32) to receive PDI204 intravenously (IV) at three different doses (200, 600, 1200 mg) or intramuscularly (IM) at 300 mg. Results: PDI204 was safe and tolerable with only Grade 1 and 2 adverse events. High serum levels of PDI204 were detected in PDI204‐dosed participants with a median elimination half‐life of 17.7 days (IQR 16.3–22.1). Boosted neutralising activity and Fc receptor binding were observed in serum against ancestral and Omicron BA.5 SARS‐CoV‐2 strains, but not against the later Omicron strain XBB.1.5. IM‐dosed subjects had peak PDI204 levels in serum 2–6 days later than IV‐dosed subjects. Entry of PDI204 into saliva from blood was low and variable, and primarily detected in participants receiving 600 mg or 1200 mg doses. Three of 32 people acquired COVID‐19 within 90 days of dosing, two receiving PDI204 and one in a placebo recipient. Conclusion: Overall, the mAb PDI204 was safe but lost activity against later Omicron strains and did not prevent COVID‐19 during this trial.
- Open Access
Predicting the efficacy of Ervebo against Bundibugyo virus disease
There is currently no clinical data for the effectiveness of the only licensed Ebola virus disease vaccine (Ervebo) against Bundibugyo virus disease. A number of studies have shown immune cross-reactivity with Bundibugyo virus after Ervebo vaccination. However, antibody recognition of Bundibugyo is around 2.8-fold lower than recognition of Ebola virus. Here, we aimed to infer how a 2.8-fold drop in immune recognition may affect Ervebo protection against Bundibugyo virus disease based on analysis of data on Ervebo immunogenicity and protection from Ebola virus disease. This work has three main components. Firstly, we analysed the timing of vaccine protection in the Ervebo pivotal ring vaccination clinical trial. Secondly, we performed a systematic review and meta-analysis of antibody responses to Ebola virus after Ervebo vaccination over time. Thirdly, we combined these data with previously reported data on the cross-reactivity to Bundibugyo virus to infer protection of Ervebo against Bundibugyo virus disease. We find that the clinical trial data for Ervebo supports vaccine protection beginning earlier than 10 days after vaccination. Secondly, binding antibody levels against Ebola virus on day 28 post vaccination (peak responses) were on average 12.9-fold (95% confidence interval, CI: 6.4 – 26.0) higher than on day 7, 6.3-fold (95% CI: 3.7 – 10.8) higher than on day 10, and 2.5-fold (95% CI: 1.4 – 4.4) higher than on day 14 (neutralising antibodies showed similar results). Finally, we consider the scenarios where antibody levels to Ebola virus at day 7 or 10 are putative protective thresholds against Ebola virus disease, and we assume these thresholds also apply for Bundibugyo virus disease. Then, with a 2.8-fold reduction of responses to Bundibugyo compared to Ebola virus, we predict antibody responses to Bundibugyo virus after Ervebo vaccination are likely above these putative protective thresholds.
Open AccessPredicting the efficacy of Ervebo against Bundibugyo virus disease
There is currently no clinical data for the effectiveness of the only licensed Ebola virus disease vaccine (Ervebo) against Bundibugyo virus disease. A number of studies have shown immune cross-reactivity with Bundibugyo virus after Ervebo vaccination. However, antibody recognition of Bundibugyo is around 2.8-fold lower than recognition of Ebola virus. Here, we aimed to infer how a 2.8-fold drop in immune recognition may affect Ervebo protection against Bundibugyo virus disease based on analysis of data on Ervebo immunogenicity and protection from Ebola virus disease. This work has three main components. Firstly, we analysed the timing of vaccine protection in the Ervebo pivotal ring vaccination clinical trial. Secondly, we performed a systematic review and meta-analysis of antibody responses to Ebola virus after Ervebo vaccination over time. Thirdly, we combined these data with previously reported data on the cross-reactivity to Bundibugyo virus to infer protection of Ervebo against Bundibugyo virus disease. We find that the clinical trial data for Ervebo supports vaccine protection beginning earlier than 10 days after vaccination. Secondly, binding antibody levels against Ebola virus on day 28 post vaccination (peak responses) were on average 12.9-fold (95% confidence interval, CI: 6.4 – 26.0) higher than on day 7, 6.3-fold (95% CI: 3.7 – 10.8) higher than on day 10, and 2.5-fold (95% CI: 1.4 – 4.4) higher than on day 14 (neutralising antibodies showed similar results). Finally, we consider the scenarios where antibody levels to Ebola virus at day 7 or 10 are putative protective thresholds against Ebola virus disease, and we assume these thresholds also apply for Bundibugyo virus disease. Then, with a 2.8-fold reduction of responses to Bundibugyo compared to Ebola virus, we predict antibody responses to Bundibugyo virus after Ervebo vaccination are likely above these putative protective thresholds.
- Open Access
- 1 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-14
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection
Controlled human influenza infection studies can uniquely interrogate the early immune factors associated with clinical outcome. In this study, 27 healthy volunteers with low strain-specific serum neutralizing antibody levels were challenged with influenza A/H3N2 virus. Twenty-two became infected, with 18 developing mild-to-moderate symptoms and four remaining asymptomatic. Local and systemic immune profiling revealed innate pathways that engaged more rapidly and to a higher level in symptomatic participants. Earlier monocyte and dendritic cell activation correlated with higher symptom scores but also enhanced natural killer and CD8 + T cell activation thereafter. At baseline, peripheral blood mononuclear cells from symptomatic participants were more responsive to in vitro challenge, indicating a predisposition to divergent immunological outcomes at the time of virus exposure that was subsequently modulated by infection. These results show that human innate cell responsiveness is a predeterminant of both symptomatic disease and cellular immune responses known to promote viral clearance, suggesting potential targets for therapeutic intervention if decoupled.
- 1 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 1-14
Open AccessInnate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection
Controlled human influenza infection studies can uniquely interrogate the early immune factors associated with clinical outcome. In this study, 27 healthy volunteers with low strain-specific serum neutralizing antibody levels were challenged with influenza A/H3N2 virus. Twenty-two became infected, with 18 developing mild-to-moderate symptoms and four remaining asymptomatic. Local and systemic immune profiling revealed innate pathways that engaged more rapidly and to a higher level in symptomatic participants. Earlier monocyte and dendritic cell activation correlated with higher symptom scores but also enhanced natural killer and CD8 + T cell activation thereafter. At baseline, peripheral blood mononuclear cells from symptomatic participants were more responsive to in vitro challenge, indicating a predisposition to divergent immunological outcomes at the time of virus exposure that was subsequently modulated by infection. These results show that human innate cell responsiveness is a predeterminant of both symptomatic disease and cellular immune responses known to promote viral clearance, suggesting potential targets for therapeutic intervention if decoupled.
- Open Access
- 5 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Atypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity
Indigenous people are disproportionately impacted by influenza viruses and chronic multimorbidity. Yet, the impact of comorbidities on immunity towards influenza vaccination is unknown. We recruited Australian First Nations and non-Indigenous people vaccinated with seasonal inactivated influenza vaccines and assessed their humoral and cellular responses in the context of comorbidities at baseline and after immunisation. Our study highlights prevalence of multimorbidity in First Nations people, associated with elevated baseline cellular activation, pro-inflammatory cytokines and agalactosylated IgG. Following vaccination, all groups had increased antibody titres and haemagglutinin-specific IgD - B-cell frequencies as compared to baseline. However, we reveal increased prevalence of pro-inflammatory atypical B cells within influenza haemagglutinin-specific IgD - B cells and lack of significant circulating T follicular helper type-1 cell activation in individuals with comorbidities, correlating with multimorbidity-associated baseline inflammatory features. Our findings thus reveal that vaccinees with comorbidities, both Australian First Nations and non-Indigenous participants, can mount antibody responses following influenza vaccination, although their cellular immune features, haemagglutinin-specific IgD - B cells and cT FH 1 compartments, display features of perturbed humoral axis functionality linked to multimorbidity-associated inflammation and IgG glycosylation patterns at baseline. Our study supports influenza vaccination for individuals with comorbidities, especially relevant to Indigenous populations with prevalent multimorbidity.
- 5 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAtypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity
Indigenous people are disproportionately impacted by influenza viruses and chronic multimorbidity. Yet, the impact of comorbidities on immunity towards influenza vaccination is unknown. We recruited Australian First Nations and non-Indigenous people vaccinated with seasonal inactivated influenza vaccines and assessed their humoral and cellular responses in the context of comorbidities at baseline and after immunisation. Our study highlights prevalence of multimorbidity in First Nations people, associated with elevated baseline cellular activation, pro-inflammatory cytokines and agalactosylated IgG. Following vaccination, all groups had increased antibody titres and haemagglutinin-specific IgD - B-cell frequencies as compared to baseline. However, we reveal increased prevalence of pro-inflammatory atypical B cells within influenza haemagglutinin-specific IgD - B cells and lack of significant circulating T follicular helper type-1 cell activation in individuals with comorbidities, correlating with multimorbidity-associated baseline inflammatory features. Our findings thus reveal that vaccinees with comorbidities, both Australian First Nations and non-Indigenous participants, can mount antibody responses following influenza vaccination, although their cellular immune features, haemagglutinin-specific IgD - B cells and cT FH 1 compartments, display features of perturbed humoral axis functionality linked to multimorbidity-associated inflammation and IgG glycosylation patterns at baseline. Our study supports influenza vaccination for individuals with comorbidities, especially relevant to Indigenous populations with prevalent multimorbidity.
- Open Access
Quantifying the association between neutralising antibodies and protection from RSV disease in infants and adults: A systematic review and meta-analysis
A number of vaccines and long-acting monoclonal antibodies have been shown to be effective in the prevention of respiratory syncytial virus (RSV) disease. However, an immune correlate of protection for RSV has not yet been identified. We conducted a systematic review to identify published reports of immunogenicity and/or efficacy in vaccines and long-acting monoclonal antibodies against RSV and performed a meta-analysis on extracted data to identify any relationship between antibody increase and protection against RSV disease. We identified 130 relevant reports which we classified into an open access evidence map of RSV immunisation products. We found a strong correlation between the immunisation induced rise in neutralising antibody titres and efficacy (ρ>0.7 for all comparisons, Spearman). For infants, we estimated that each 10-fold increase in neutralising antibody titre rise provides an additional 31% [95% CI 10%, 47%], 47% [95% CI 36%, 56%] and 57% [95% CI 45%, 66%] reduction in the relative risk of symptomatic, moderate and severe disease respectively. For older adults, a 10-fold rise in antibody levels was associated with a 34% [95% CI -2%, 57%], 50% [95% CI 22%, 67%] and 63% [95% CI 36%, 79%] reduction in the relative risk of RSV disease with 1, 2 and 3 symptoms respectively. These results align extremely well with findings from natural history studies and individual-based analysis of correlates of protection studies. This work paves the way for use of neutralising antibodies as a correlate of protection to guide the development, approval, and deployment of RSV vaccines and monoclonal antibodies.
Open AccessQuantifying the association between neutralising antibodies and protection from RSV disease in infants and adults: A systematic review and meta-analysis
A number of vaccines and long-acting monoclonal antibodies have been shown to be effective in the prevention of respiratory syncytial virus (RSV) disease. However, an immune correlate of protection for RSV has not yet been identified. We conducted a systematic review to identify published reports of immunogenicity and/or efficacy in vaccines and long-acting monoclonal antibodies against RSV and performed a meta-analysis on extracted data to identify any relationship between antibody increase and protection against RSV disease. We identified 130 relevant reports which we classified into an open access evidence map of RSV immunisation products. We found a strong correlation between the immunisation induced rise in neutralising antibody titres and efficacy (ρ>0.7 for all comparisons, Spearman). For infants, we estimated that each 10-fold increase in neutralising antibody titre rise provides an additional 31% [95% CI 10%, 47%], 47% [95% CI 36%, 56%] and 57% [95% CI 45%, 66%] reduction in the relative risk of symptomatic, moderate and severe disease respectively. For older adults, a 10-fold rise in antibody levels was associated with a 34% [95% CI -2%, 57%], 50% [95% CI 22%, 67%] and 63% [95% CI 36%, 79%] reduction in the relative risk of RSV disease with 1, 2 and 3 symptoms respectively. These results align extremely well with findings from natural history studies and individual-based analysis of correlates of protection studies. This work paves the way for use of neutralising antibodies as a correlate of protection to guide the development, approval, and deployment of RSV vaccines and monoclonal antibodies.
- Open Access
Recent thymic emigrants are preferentially recruited into the memory pool during persistent infection
Cytomegalovirus (CMV) leads to a unique phenomenon known as ‘memory inflation,’ where antigen-specific memory CD8+ T cells continue to accumulate in the peripheral tissues during the latent stage of infection. However, it is still not clear how the inflating pool of memory CD8+ T cells is generated and maintained. In this study, we used murine cytomegalovirus (MCMV) as a model of persistent infection and fate-mapping mice to determine the dynamics of CD8+ T cell recruitment into the memory pool. We found that neonatal exposure to CMV leads to an expansion of newly made CD8+ T cells (recent thymic emigrants, RTEs), which are maintained in the long-lived memory compartment. In contrast, CD8+ T cells made during the latent phase of infection (mature CD8+ T cells) contribute little to the memory pool. We also observed notable phenotypic differences between RTEs and mature cells. Whereas RTEs present at the time of infection gave rise to more effector memory cells, the cells produced later in infection were biased towards becoming central memory cells. Importantly, the preferential recruitment of RTEs into the effector memory pool also occurs during adult exposure to CMV. Collectively, these data demonstrate that persistent infection expands the RTE population, and timing of infection dictates whether neonatal or adult RTEs are ‘locked in’ to the memory pool. Author Summary Following infection with CMV, CD8+ T cells accumulate in the blood and peripheral organs over time, a feature termed ‘memory inflation’. However, it is not clear whether memory inflation is due to the continuous recruitment of cells made during the latent stage of infection or expansion of CD8+ T cells that were present at the time of infection. To address this question, we used a fate-mapping mouse model and examined the recruitment of CD8+ T cells that were produced during different stages of infection. Surprisingly, we discovered that CD8+ T cells exported from the thymus just prior to infection are preferentially recruited and maintained in the memory pool. In contrast, CD8+ T cells made during the latent stage contribute minimally to the inflating pool and exhibit a less differentiated phenotype. These results provide a new conceptual framework for understanding how the memory pool is generated and maintained after persistent viral infection.
Open AccessRecent thymic emigrants are preferentially recruited into the memory pool during persistent infection
Cytomegalovirus (CMV) leads to a unique phenomenon known as ‘memory inflation,’ where antigen-specific memory CD8+ T cells continue to accumulate in the peripheral tissues during the latent stage of infection. However, it is still not clear how the inflating pool of memory CD8+ T cells is generated and maintained. In this study, we used murine cytomegalovirus (MCMV) as a model of persistent infection and fate-mapping mice to determine the dynamics of CD8+ T cell recruitment into the memory pool. We found that neonatal exposure to CMV leads to an expansion of newly made CD8+ T cells (recent thymic emigrants, RTEs), which are maintained in the long-lived memory compartment. In contrast, CD8+ T cells made during the latent phase of infection (mature CD8+ T cells) contribute little to the memory pool. We also observed notable phenotypic differences between RTEs and mature cells. Whereas RTEs present at the time of infection gave rise to more effector memory cells, the cells produced later in infection were biased towards becoming central memory cells. Importantly, the preferential recruitment of RTEs into the effector memory pool also occurs during adult exposure to CMV. Collectively, these data demonstrate that persistent infection expands the RTE population, and timing of infection dictates whether neonatal or adult RTEs are ‘locked in’ to the memory pool. Author Summary Following infection with CMV, CD8+ T cells accumulate in the blood and peripheral organs over time, a feature termed ‘memory inflation’. However, it is not clear whether memory inflation is due to the continuous recruitment of cells made during the latent stage of infection or expansion of CD8+ T cells that were present at the time of infection. To address this question, we used a fate-mapping mouse model and examined the recruitment of CD8+ T cells that were produced during different stages of infection. Surprisingly, we discovered that CD8+ T cells exported from the thymus just prior to infection are preferentially recruited and maintained in the memory pool. In contrast, CD8+ T cells made during the latent stage contribute minimally to the inflating pool and exhibit a less differentiated phenotype. These results provide a new conceptual framework for understanding how the memory pool is generated and maintained after persistent viral infection.
- Open Access
- 7 January 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (4)
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
BACKGROUND: The immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are more immunogenic if given in the same arm or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when coformulated and codelivered. METHODS: We randomly assigned 56 adults to receive the Afluria quadrivalent inactivated influenza and Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccines, either in opposite arms or both in the same arm at the same site. The primary endpoint was the difference in median combined serum hemagglutination inhibition titer to the H1, H3, and B-Vic vaccine influenza strains after vaccination. RESULTS: We found no significant difference in hemagglutination inhibition antibody levels between the groups ( P = 0.30), with the same-arm group having a 1.26-fold higher titer than the opposite-arm group. There were no differences in analyses of antibodies against individual influenza strains or in nasal or saliva antibody levels. While both binding and neutralizing antibody titers against SARS-CoV-2 were not significantly different between groups postvaccination, there was a higher fold-change in BA.5 and ancestral strain neutralizing antibodies in the opposite-arm group. CONCLUSION: Influenza vaccination is equivalently immunogenic if given in the same arm or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site from influenza vaccines. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12624000445572. FUNDING: Australian National Health and Medical Research Council, Australian Medical Research Future Fund, and National Institutes of Health (UH2AI176172).
- 7 January 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (4)
Open AccessRandomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
BACKGROUND: The immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are more immunogenic if given in the same arm or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when coformulated and codelivered. METHODS: We randomly assigned 56 adults to receive the Afluria quadrivalent inactivated influenza and Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccines, either in opposite arms or both in the same arm at the same site. The primary endpoint was the difference in median combined serum hemagglutination inhibition titer to the H1, H3, and B-Vic vaccine influenza strains after vaccination. RESULTS: We found no significant difference in hemagglutination inhibition antibody levels between the groups ( P = 0.30), with the same-arm group having a 1.26-fold higher titer than the opposite-arm group. There were no differences in analyses of antibodies against individual influenza strains or in nasal or saliva antibody levels. While both binding and neutralizing antibody titers against SARS-CoV-2 were not significantly different between groups postvaccination, there was a higher fold-change in BA.5 and ancestral strain neutralizing antibodies in the opposite-arm group. CONCLUSION: Influenza vaccination is equivalently immunogenic if given in the same arm or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site from influenza vaccines. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12624000445572. FUNDING: Australian National Health and Medical Research Council, Australian Medical Research Future Fund, and National Institutes of Health (UH2AI176172).
- Top Cited Papers
- 2 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (92) , eadj9285
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance. Here, we performed intranasal inoculation of 34 young adult, seronegative volunteers with a pre-Alpha severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. Of these participants, 18 (53%) became infected and showed an interferon-dominated mediator response with divergent kinetics between nasal and systemic sites. Peripheral CD4 + and CD8 + T cell activation and proliferation were early and robust but showed distinct kinetic and phenotypic profiles; antigen-specific T cells were largely CD38 + Ki67 + and displayed central and effector memory phenotypes. Both mucosal and systemic antibodies became detectable around day 10, but nasal antibodies plateaued after day 14 while circulating antibodies continued to rise. Intensively granular measurements in nasal mucosa and blood allowed modeling of immune responses to primary SARS-CoV-2 infection that revealed CD8 + T cell responses and early mucosal IgA responses strongly associated with viral control, indicating that these mechanisms should be targeted for transmission-reducing intervention.
- 2 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (92) , eadj9285
Top Cited PapersMucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance. Here, we performed intranasal inoculation of 34 young adult, seronegative volunteers with a pre-Alpha severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. Of these participants, 18 (53%) became infected and showed an interferon-dominated mediator response with divergent kinetics between nasal and systemic sites. Peripheral CD4 + and CD8 + T cell activation and proliferation were early and robust but showed distinct kinetic and phenotypic profiles; antigen-specific T cells were largely CD38 + Ki67 + and displayed central and effector memory phenotypes. Both mucosal and systemic antibodies became detectable around day 10, but nasal antibodies plateaued after day 14 while circulating antibodies continued to rise. Intensively granular measurements in nasal mucosa and blood allowed modeling of immune responses to primary SARS-CoV-2 infection that revealed CD8 + T cell responses and early mucosal IgA responses strongly associated with viral control, indicating that these mechanisms should be targeted for transmission-reducing intervention.
- Open Access
- 11 July 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (17)
Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
BACKGROUND: There is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improved immunity with a longer interval between the first and second vaccine doses. METHODS: We conducted a randomized, controlled trial (November 2022–August 2023) and assigned 52 fully vaccinated adults to an immediate or a 3-month delayed bivalent Spikevax mRNA booster vaccine. Follow-up visits were completed for 48 participants ( n = 24 per arm), with collection of saliva and plasma samples following each visit. RESULTS: The rise in neutralizing antibody responses to ancestral and Omicron strains were almost identical between the immediate and delayed vaccination arms. Analyses of plasma and salivary antibody responses (IgG, IgA), plasma antibody-dependent phagocytic activity, and the decay kinetics of antibody responses were similar between the 2 arms. Symptomatic and asymptomatic SARS-CoV-2 infections occurred in 49% (21 of 49) participants over the median 11.5 months of follow-up and were also similar between the 2 arms. CONCLUSIONS: Our data suggest that there was no benefit in delaying COVID-19 mRNA booster vaccination in preimmune populations during the present endemic phase of COVID-19. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry number 12622000411741 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000411741). FUNDING: National Health and Medical Research Council, Australia (program grant App1149990) and Medical Research Future Fund (App2005544).
- 11 July 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (17)
Open AccessRandomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
BACKGROUND: There is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improved immunity with a longer interval between the first and second vaccine doses. METHODS: We conducted a randomized, controlled trial (November 2022–August 2023) and assigned 52 fully vaccinated adults to an immediate or a 3-month delayed bivalent Spikevax mRNA booster vaccine. Follow-up visits were completed for 48 participants ( n = 24 per arm), with collection of saliva and plasma samples following each visit. RESULTS: The rise in neutralizing antibody responses to ancestral and Omicron strains were almost identical between the immediate and delayed vaccination arms. Analyses of plasma and salivary antibody responses (IgG, IgA), plasma antibody-dependent phagocytic activity, and the decay kinetics of antibody responses were similar between the 2 arms. Symptomatic and asymptomatic SARS-CoV-2 infections occurred in 49% (21 of 49) participants over the median 11.5 months of follow-up and were also similar between the 2 arms. CONCLUSIONS: Our data suggest that there was no benefit in delaying COVID-19 mRNA booster vaccination in preimmune populations during the present endemic phase of COVID-19. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry number 12622000411741 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000411741). FUNDING: National Health and Medical Research Council, Australia (program grant App1149990) and Medical Research Future Fund (App2005544).
- Open Access
- 10 April 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (3) , 415-428
B-cell characteristics define HCV reinfection outcome
- 10 April 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (3) , 415-428
Open AccessB-cell characteristics define HCV reinfection outcome